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Is transdifferentiation in trouble?
 
Spectacular examples of transdiffer-
entiation—such as brain cells turning
to blood and blood to brain—have
given way to sneaking suspicions
about artifacts in culture, fusion, and
clonality. Could cell fates be relatively
ﬁxed after all?
 
The exact fate map of 
 
Caenorhabditis 
elegans
 
 is a dream for developmental 
biology control freaks. Stem cells, which 
can both self-renew and produce a 
particular set of differentiated progeny, 
seemed like the mammalian equivalent, 
albeit a little more malleable and messy.
But lately this view of development as 
a controlled series of fate maps, with each 
cell type performing one and only one 
function, has come under attack. Stem 
cell researchers have claimed that brain 
can be turned into blood (Bjornson et al., 
1999), and blood into brain (Brazelton et 
al., 2000; Mezey et al., 2000; Priller et 
al., 2001), muscle (Ferrari et al., 1998), 
myocardium (Orlic et al., 2001) or liver 
(Lagasse et al., 2000). In the hands of 
some investigators, bone marrow (Krause 
et al., 2001) and neural stem cells (Clarke 
et al., 2000) can apparently turn into 
pretty much everything.
“I believe this phenomenon was 
missed for a very long time,” says Helen 
Blau (Stanford University, Stanford, 
CA), “because we didn’t have the 
imagination to think that it could 
happen or the tools to prove it.” The 
orgy of plasticity has prompted Blau to 
propose a new way of thinking about cell 
fate determination (Blau et al., 2001), 
with stem cell capability existing as a 
switch that can be turned on and altered 
as easily as an apoptotic program.
But others see at least some of the 
reports of cell fate changes—also known 
as transdifferentiation—as simply sloppy 
science. “The emphasis,” says Sean 
Morrison (University of Michigan, Ann 
Arbor, MI), “has been on describing 
spectacular results rather than on 
describing it in an evenhanded way that 
would identify the real importance of the 
phenomenon.” Several dissenters have 
called for more stringent criteria for 
judging transdifferentiation experiments 
(Anderson, 2001; Anderson et al., 2001).
As follow-up studies emerge, questions 
have been raised about some of the earlier 
results. The verdict is not in yet, but the 
resolution of this debate will have impli-
cations on several fronts, determining our 
view of basic stem cell biology, affecting 
the strategy for treating patients with 
stem cell therapies, and influencing the 
steps used by the United States Congress 
to regulate stem cell research.
 
Political science and 
medical treatments
 
Transdifferentiation is of interest to 
Senate Select Committees because it 
could mean that embryonic stem cells 
(ESCs) are not needed for cellular 
therapies. If adult stem cells (ASCs) can 
turn into anything, why bother with the 
controversial ESCs? Unfortunately, says 
Darwin Prockop (MCP Hahnemann 
University, Philadelphia, PA), “the 
political debate over embryonic stem 
cells and adult stem cells has led both 
sides to overstate their cases.” In an 
effort to protect ESC research, “some 
of these [transdifferentiation] results 
have been criticized too heavily.”
The burgeoning literature supporting 
plasticity has made life harder for 
scientists seeking to protect the right 
to conduct ESC research. “Constantly 
thrown at us is ‘you can do everything 
with adult stem cells’—not by anyone 
in the scientific community, but it’s 
picked up by politicians and lobbying 
groups,” says Austin Smith (University of 
Edinburgh, UK). “And it’s quite difficult 
to argue against because they will just list 
all these published papers”—many of 
which Smith believes are incorrect.
Choosing one field over another is 
probably the wrong way to go in any 
case. “All the research should go on in 
parallel,” says Blau. “We don’t know 
what will work best.”
Even if one remedy won’t work for 
every disease, any specific treatment 
would still need to generate the desired 
cell type at a therapeutically meaningful 
frequency. Markus Grompe (Oregon 
Health Sciences University, Portland, 
OR) is not sure that this will always be 
possible with ASCs. “We think that 
transdifferentiation occurs, but the levels 
are three to four orders of magnitude less 
than has been reported by others.”
If Grompe is correct, many of the 
proposed therapies may not work. “If 
we’re overstating the efficiency of 
replacement by one or two orders of 
magnitude,” says Morrison, “it won’t 
be sufficient—we won’t be able to cure 
people this way.”
 
The ins and outs of 
cell fate determination
 
And then there are the implications 
for basic stem cell biology. For Ron 
McKay (National Institutes of Health, 
Bethesda, MD), transdifferentiation 
results represented a much-needed 
correction from the excesses of molecular 
biology. “There has been a tendency to 
believe in the inviolability of how an 
organism is constructed,” he says, with 
cell fates seen as predetermined based 
on the particular set of transcription 
factors turned on in a certain stem cell. 
This view was bolstered by some earlier 
experiments in which transplanted cells 
failed to switch fates.
But some of this inflexibility may have 
been caused by a local microenvironment 
that, along with a particular set of 
factors, was transplanted with the cells 
(Trainor et al., 2002). When researchers 
tracked individual cells traveling into 
new tissues, they saw the unexpected 
fate switches, and the focus shifted to 
the importance of extracellular signals.
 
Cellular plasticity is 
 
under attack. 
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This debate between intrinsic and 
extrinsic determinants “is going to have 
to be sorted out on a case by case 
basis,” says David Anderson (California 
Institute of Technology, Pasadena, 
CA). In his view, “the idea that any cell 
type can make any other cell type given 
the correct extrinsic signal is unlikely to 
be right.” Such a scenario would, he 
points out, lead to extremely confused 
migratory cells, which would be unable 
to reach their destinations without 
becoming several different cell types 
while en route. Many embryonic 
differentiation signals or developmental 
gradients are no longer present in the 
adult, making Anderson wonder how 
proposed transdifferentiations in non-
regenerating tissues might be directed.
 
New standards for a new field
 
These theoretical considerations are not 
the only ones troubling the field. The 
earliest examples of transdifferentiation 
were so unexpected and dramatic that 
only now is the community determining 
the criteria required to demonstrate 
bona fide fate changes. Earlier standards 
have been found wanting.
The new transdifferentiation 
manifesto has three elements. Ideally, 
introduced cells must be clonal, 
prospectively isolated (i.e, by sorting 
for marker proteins, without any in 
vitro culturing), and tracked until 
they can be shown to be functioning 
in their new environment.
Not all researchers are signing on to 
this program. Blau, for example, says that 
studies with hematopoietic (blood-
forming) stem cells (HSCs) have only 
recently met these requirements after 
20 years of research, whereas most 
ASC research is only a couple of years 
old. “The clonal experiments are 
incredibly hard to do,” she says. 
“Ultimately it would be nice to 
know, but it’s something to work 
toward.”
Until clonality is accomplished, 
most existing studies have used 
mixed populations of cells, such as 
bone marrow. Thus it is possible or even 
probable that any neural cells arise not 
from HSCs, but from mesenchymal 
stem cells that are also present in bone 
marrow.
In at least one case, tracking the stem 
cell to its source has negated an earlier 
claim of transdifferentiation. Muscle 
can turn into blood, says Margaret 
Goodell (Baylor College of Medicine, 
Houston, TX), only because of the 
presence of roving HSCs interspersed 
in the muscle cells (McKinney-Freeman 
et al., 2002). “Many people are happy 
to see our results, because it casts some 
doubts on the results that are out 
there,” says Goodell. Even if a case of 
transdifferentiation holds up, she says, 
the clonal analysis is vital, because “you 
need to know the cell type so you can 
improve the efficiency.”
The cell type can be defined only 
with better isolation methods and cell 
surface markers. These markers, in turn, 
allow for prospective isolation of cells 
without intervening culture. Although 
neural stem cells have recently been 
isolated prospectively (Uchida et al., 
2000; Rietze et al., 2001), most studies 
have used cells that have been extensively 
cultured. “You cannot be sure the same 
thing would happen if [the cells] hadn’t 
been cultured,” says Jonas Frisén 
(Karolinska Institute, Stockholm, 
Sweden). “It’s looking at what is 
possible rather than what is happening.”
One of the first and most spectacular 
examples of transdifferentiation has 
recently come under attack for just this 
reason. The demonstration that brain 
can be turned into blood (Bjornson et 
al., 1999) could not be replicated by 
Derek van der Kooy and colleagues 
(University of Toronto, Canada) when 
they used shorter passage times. As the 
cells were passaged for longer, however, 
they gradually accumulated changes in 
various growth properties, leading the 
authors to suggest that rare genetic or 
epigenetic events might trigger the 
neural-to-blood fate switch (Morshead 
et al., 2002). As a result, says van der 
Kooy, “I’ve completely reversed my 
view of what I thought was a very 
convincing piece of data.”
Others feel that additional studies 
will fall to a similar analysis. “My 
prediction would be that people will be 
much more hard-pressed to identify 
these transdifferentiation phenomena 
once they are using noncultured cells,” 
says Morrison.
Some of the most convincing clonal 
results have come from Diane Krause 
(Yale University, New Haven, CT), 
who showed that single marked cells 
that home to bone marrow can be 
transplanted to yield epithelial cells in 
various organs (Krause et al., 2001). 
This unorthodox method of cell 
isolation does, however, mean that 
other questions remain. As Krause 
herself says: “Whether that homing is 
necessary for plasticity, we just don’t 
know.”
Culture-related changes may also taint 
the results of Catherine Verfaillie 
(University of Minnesota, Minneapolis, 
MN). She isolated a bone-marrow 
derived cell that has been dubbed the 
“ultimate stem cell” (Pagán-Westphal, 
2002) because of its ability to generate 
cells of so many different tissues. Isolation 
through culture may skew ideas about 
basic biology, but changes to cells in 
culture may not prevent therapeutic 
applications, and Verfaillie’s cells may 
well find important uses in medicine.
 
Technical difficulties
 
The third requirement—that researchers 
demonstrate evidence of functionality—
has been at least partially answered in a 
recent study in the 
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. Priller et al. 
(2001) demonstrated that a marked 
bone marrow cell could end up as a 
highly differentiated Purkinje cell in 
the brain (Fig. 1 A). But this study 
raised an additional concern—this 
time about possible cell fusion events. 
“Stem cells are the most long-lived 
cells,” says van der Kooy, “and occasion-
ally they will fuse with host cells.”
“We haven’t really ruled out fusion,” 
says Josef Priller (Humboldt University, 
Berlin, Germany). “It’s really on 
probability grounds that we can 
argue—it’s really not known at all 
that brain cells fuse.”
The cells introduced in Priller’s
experiments were genetically identical to 
the cells of the recipient (except for the 
GFP marker), so any possible fusion  
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events are difficult to track. There is 
further concern given that Priller has 
not yet observed intermediate stages of 
Purkinje cell development with the 
introduced cells, although this could be 
explained by the limited time points 
studied. Blau has performed similar 
experiments and seen that some (but 
certainly not all) of the marked Purkinje 
cells have greater than 2N DNA. This 
may not be surprising, however, as 
greater than 2N DNA content can 
occur normally in Purkinje cells.
Krause is doing experiments to rule 
out the possibility of fusion in her 
experiments. For now, she says, “we 
haven’t published any experiments to 
specifically rule [fusion] in or out.”
The possibility that fusion events 
might occur has been boosted by two 
recent reports one from Smith and 
another from Naohiro Terada 
(University of Florida, Gainesville, FL) 
and colleagues. Smith found that neural 
stem cells cocultured with embryonic 
stem (ES) cells could contribute to non-
neural tissues not by dedifferentiation 
but via fusion with the ES cells (Fig. 1 
B; Ying et al., 2002). Terada carried out 
similar coculture experiments with 
bone marrow cells and ES cells and 
found that the resulting ES-like cells, 
which could differentiate to many 
different cell types in vitro, were 
tetraploid or hexaploid (Terada et al., 
2002). Smith points out that in vivo 
situations might be more or less 
permissive for cell fusion, but he believes 
that the frequency of reported trans-
differentiation events is “not inconsistent” 
with the frequency of fusion events that 
he sees. “We cannot say that [fusion] 
explains the phenomenon that others 
have reported,” he says. “But in none of 
the other experiments can cell fusion be 
ruled out, so it’s therefore possible that 
many of these reports could be explained 
by cell fusion.”
Whereas marked cells with 
complicated morphology could arise 
via fusion, marked cells with simpler 
morphology can be mistaken based on 
signal overlap. “Even when you are 
being careful it’s still possible to 
incorrectly identify cells because nuclei 
can be so adjacent,” says Morrison. A 
similar problem has recently been seen 
in neurogenesis experiments—a follow-
up study has shown that replicating cells 
in certain parts of the brain are not 
neurons but support cells that are very 
close to neurons (Kornack and Rakic, 
2001). Although there is a trivial step 
that could rule out signal overlap—
checking cells for continuing costaining 
after dispersal on slides—most trans-
differentiation studies do not include 
this procedure.
Immunofluorescence studies can also 
lead to false positives when an arbitrary 
cut-off for positive staining is set too 
low. “From the liver angle, I know 
people have overestimated the extent 
of [transdifferentiation],” says Grompe, 
“so it makes me wonder about the other 
tissues.” Grompe’s frequency estimates 
are based on the number of clonal 
patches rather than on absolute numbers 
of marked cells in the livers he has 
studied. The transdifferentiation events 
are extremely rare, but with selection 
present in these experiments the cells 
can become more numerous and func-
tionally important. Grompe says that 
without selection (such as the use of 
hepatotoxic drugs), transdifferentiation
is unlikely to translate into medically 
important treatments. Selection may be 
difficult to engineer for some proposed 
therapeutic sites, such as the brain.
 
Picking through the rubble
 
In theory, transdifferentiation could
be detected as a complication of bone 
marrow transplant procedures. But a 
1–2% replacement rate—as claimed in 
many transdifferentiation reports—was 
never noted by transplantation pioneers. 
This reassures Grompe that plasticity 
is limited. “I’m glad we don’t have 
cells differentiating everywhere after 
transplantation,” he says.
Smith also feels that plasticity reports 
had gone too far. “I find it a little 
surprising that people had so readily 
discarded everything that developmental 
biology had established over the past 20 
years—that cells are generally lineage 
restricted,” he says. Now he feels that 
the balance is beginning to swing back.
But even transdifferentiation’s critics 
are far from outright pessimists. The 
spirit of many of these researchers is 
captured by van der Kooy. “Right now 
is a very exciting time,” he says. “There 
are so many reports of plasticity that not 
all of them can be wrong due to these 
problems. We just have to look at all of 
them very carefully.” Blau is concerned 
that current criticisms should not 
dampen the enthusiasm of those in the 
field and says that careful analysis using 
confocal microscopy and genetic 
marking of transplants should improve 
the results in more recent studies. “We 
should be as rigorous as possible, but we 
shouldn’t turn our backs on this,” she 
says. “To slam a field because it’s new 
and you haven’t proven everything is 
also bad science.”
Rossi feels that the reliability of the 
studies depends in part on the direction 
of the claimed transformation. “Most 
Figure 1. Plasticity or fusion? Marked bone marrow cells can become differentiated 
Purkinje cells (A), but another case of apparent plasticity—neural stem cells contributing to 
various tissues of a chimeric mouse (B)—occurs only after the neural cells have fused with 
cocultured embryonic stem cells.
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of the reports of other cell types 
making blood have been put in doubt 
in the last year or so,” he says, “but the 
[work showing] blood making other 
cells is pretty robust.”
 
A physiological function
 
Plasticity has extraordinary consequences 
for cell biology theory and medical 
treatment, but what is the physiological 
significance for the organism? Are 
transdifferentiation events used for 
any purpose in living animals?
There are at least two trivial 
explanations for transdifferentiation. 
First, brain cells might normally have a 
restricted potential simply because they 
are stuck within the brain. Only when 
this geographical restraint is relaxed (e.g., 
because stem cells are injected intrave-
nously) are other options open to them. 
Second, transdifferentiation may reflect a 
certain error rate in cell specification that 
was not detectable before sensitive molec-
ular biological tools were available.
Then come the more interesting 
explanations. In Prockop’s opinion, 
bone marrow cells “look as though 
they are part of a normal repair 
system.” Consistent with this, Krause 
has seen increased engraftment 
efficiency after tissue damage. The 
bone marrow might be a good place 
to store such a repair team, as the 
cells are highly mobile.
Grompe, however, has looked at the 
issue of repair more closely and found 
that transdifferentiation occurs at a low 
frequency that is not dependent on 
tissue injury. Only with more chronic 
liver damage, over nine months, does he 
see significant bone-marrow–derived 
replacement. “It’s possible that the 
precursor pool in the liver gets replaced 
by stem cells from the bone marrow in a 
stochastic process all the time,” he says. 
“If there is a physiological relevance for 
this I think it may be in very long term 
replenishment. The replacement rate 
does not appear to be injury driven.”
 
Future experiments
 
As part of studying the normal function 
of transdifferentiation, several researchers 
have their eyes on the types of parabiosis 
experiments used to study HSC 
trafficking. In these experiments the 
blood systems of two mice are joined 
artificially, so that cells can traffic from 
one marked mouse to another unmarked 
mouse, without the interference of cell 
injections or radiation treatments.
Along with these in vivo studies will 
come in vitro work to define the local 
signals that drive transdifferentiations. 
Rossi speculates that these signals are 
perturbed in disease. “Once you 
isolate these cells you can identify the 
mechanisms that drive the transdif-
ferentiation,” he says. “If you can 
supply the signals in vitro and prime 
the cells to do something, there is a 
possibility to bypass the messed up 
microenvironment. That is clearly 
the main goal of the field.”
It should be possible, says McKay, to 
derive the equivalent of thermodynamic 
models for each of these transitions. 
Although the models might be generaliz-
able, McKay suspects that the rate 
constants will vary widely depending 
on the cell type involved. “Not all fates 
are equally probable,” he says. “If you 
imagine a landscape with 200 fates on 
it, a given cell may not have equal 
access to all fates.”
Thus the debate over transdifferen-
tiation may be cast not in black and 
white—does it happen or does it 
not happen—but more in shades of 
gray. “People want completely simple 
answers,” says McKay, “but I think 
one has to be careful not to generalize.”
 
William A. Wells
wellsw@rockefeller.edu
 
References
 
Anderson, D.J. 2001. Stem cells and pattern formation
in the nervous system: the possible versus the actual.
 
Neuron.
 
 30:19–35.
Anderson, D.J., F.H. Gage, and I.L. Weissman.
2001. Can stem cells cross lineage boundaries? 
 
Nat.
Med.
 
 7:393–395.
Bjornson, C.R., R.L. Rietze, B.A. Reynolds, M.C.
Magli, and A.L. Vescovi. 1999. Turning brain into
blood: a hematopoietic fate adopted by adult neural
stem cells in vivo. 
 
Science.
 
 283:534–537.
Blau, H.M., T.R. Brazelton, and J.M. Weimann.
2001. The evolving concept of a stem cell: entity or
function? 
 
Cell.
 
 105:829–841.
Brazelton, T.R., F.M. Rossi, G.I. Keshet, and H.M.
Blau. 2000. From marrow to brain: expression of
neuronal phenotypes in adult mice. 
 
Science.
 
 290:
1775–1779.
Clarke, D.L., C.B. Johansson, J. Wilbertz, B. Veress,
E. Nilsson, H. Karlstrom, U. Lendahl, and J.
Frisén. 2000. Generalized potential of adult neural
stem cells. 
 
Science.
 
 288:1660–1663.
Ferrari, G., G. Cusella-De Angelis, M. Coletta, E.
Paolucci, A. Stornaiuolo, G. Cossu, and F. Mavilio.
1998. Muscle regeneration by bone marrow-derived
myogenic progenitors. 
 
Science.
 
 279:1528–1530.
Kornack, D.R., and P. Rakic. 2001. Cell proliferation
without neurogenesis in adult primate neocortex.
 
Science.
 
 294:2127–2130.
Krause, D.S., N.D. Theise, M.I. Collector, O.
Henegariu, S. Hwang, R. Gardner, S. Neutzel,
and S.J. Sharkis. 2001. Multi-organ, multi-lineage
engraftment by a single bone marrow-derived
stem cell. 
 
Cell.
 
 105:369–377.
Lagasse, E., H. Connors, M. Al-Dhalimy, M. Reitsma,
M. Dohse, L. Osborne, X. Wang, M. Finegold, I.L.
Weissman, and M. Grompe. 2000. Purified hemato-
poietic stem cells can differentiate into hepatocytes
in vivo. 
 
Nat. Med.
 
 6:1229–1234.
McKinney-Freeman, S.L., K.A. Jackson, F.D. Ca-
margo, G. Ferrari, F. Mavilio, and M.A. Goodell.
2002. Muscle-derived hematopoietic stem cells are
hematopoietic in origin. 
 
Proc. Natl. Acad. Sci. USA.
 
99:1341–1346.
Mezey, E., K.J. Chandross, G. Harta, R.A. Maki, and
S.R. McKercher. 2000. Turning blood into brain:
cells bearing neuronal antigens generated in vivo
from bone marrow. 
 
Science.
 
 290:1779–1782.
Morshead, C.M., P. Benveniste, N.N. Iscove, and D.
van der Kooy. 2002. Hematopoietic competence is
a rare property of neural stem cells that may depend
on genetic and epigenetic alterations. 
 
Nat. Med.
 
8:268–273.
Orlic, D., J. Kajstura, S. Chimenti, I. Jakoniuk,
S.M. Anderson, B. Li, J. Pickel, R. McKay, B.
Nadal-Ginard, D.M. Bodine, et al. 2001. Bone
marrow cells regenerate infarcted myocardium.
 
Nature.
 
 410:701–705.
Pagán-Westphal, S. 2002. Ultimate stem cell discovered.
 
New Sci.
 
 173:4.
Priller, J., D.A. Persons, F.F. Klett, G. Kempermann,
G.W. Kreutzberg, and U. Dirnagl. 2001. Neogene-
sis of cerebellar Purkinje neurons from gene-marked
bone marrow cells in vivo. 
 
J. Cell Biol.
 
 155:733–738.
Rietze, R.L., H. Valcanis, G.F. Brooker, T. Thomas,
A.K. Voss, and P.F. Bartlett. 2001. Purification of a
pluripotent neural stem cell from the adult mouse
brain. 
 
Nature.
 
 412:736–739.
Terada, N., T. Hamazaki, M. Oka, M. Hoki, D.M.
Mastalerz, Y. Nakano, E.M. Meyer, L. Morel, B.E.
Petersen, and E.W. Scott. 2002. Bone marrow cells
adopt the phenotype of other cells by spontaneous
cell fusion. 
 
Nature
 
. 10.1038/nature730.
Trainor, P.A., L. Ariza-McNaughton, and R. Krum-
lauf. 2002. Role of the isthmus and FGFs in resolv-
ing the paradox of neural crest plasticity and prepat-
terning. 
 
Science.
 
 295:1288–1291.
Uchida, N., D.W. Buck, D. He, M.J. Reitsma, M.
Masek, T.V. Phan, A.S. Tsukamoto, F.H. Gage,
and I.L. Weissman. 2000. Direct isolation of hu-
man central nervous system stem cells. 
 
Proc. Natl.
Acad. Sci. USA.
 
 97:14720–14725.
Ying, Q.-L., J. Nichols, and A.G. Smith. 2002.
Changing potency by spontaneous fusion. 
 
Nature
 
.
10.1038/nature729. 